Gitnux/Report 2026

At Home Blood Testing Industry Statistics

The global at-home blood collection kits and devices market is estimated at $210.1 million in 2026, explore the latest figures behind growth, companies and trends.
12Statistics
20Sources
3Sections
1Visuals
14mRead
At Home Blood Testing Industry Statistics
How this report is researched
01Editorial Scope

Gitnux editors write the brief first: the topic, the inclusion rules, and the frame for what belongs.

02Source Research

Agents search the published record and log every extracted figure back to the passage it came from.

Read our full methodology →

Search agents attach provenance to every extracted figure.

Next review: within 44 days

01 Industry overview

The at home blood testing industry at a glance

The global at-home blood collection kits and devices market is estimated at $210.1 million in 2026, with growth supported by self-collection, chronic-disease monitoring and decentralized healthcare.

$193.4M[2]
Market size, 2025
$210.1M[2]
Market estimate, 2026
8.9%[2]
Forecast CAGR, 2026–2033
39.1%[2]
North America share, 2025
Market size
The global at-home blood collection kits and devices market was valued at $193.4 million in 2025 and is estimated at $210.1 million in 2026. The figures cover products such as dried blood spot kits and microsampling devices rather than the broader clinical laboratory market.[2]
Forecast & CAGR
The market is forecast to reach $382.0 million by 2033, representing an 8.9% compound annual growth rate from 2026 to 2033. Growth is linked to telehealth, remote patient monitoring and decentralized clinical trials.[2]
Market share & regions
North America held the largest regional share at 39.1% of revenue in 2025, with the United States identified as the largest country market. The region benefits from decentralized healthcare adoption and established home-health infrastructure.[2]
Segmentation
Dried blood spot kits represented the largest product segment at 39.9% in 2025. Chronic-disease monitoring accounted for 38.5% by application, while self-collection devices led by device type with a 60.2% share.[2]
Pricing
Quest Diagnostics charges a $79 fee for in-home sample collection and shipment of samples to a Quest laboratory; laboratory testing is billed separately. Function Health advertises membership at $365 per year, including access to more than 160 laboratory tests, illustrating the range between fee-based collection and subscription models.[6][7]
Trends, drivers & challenges
The market is being driven by patient demand for convenient collection, telehealth and remote monitoring, with self-collection devices already holding 60.2% of the 2025 device market. A continuing challenge is expanding reliable fingerstick and microsampling performance across a wider range of analytes while maintaining laboratory-quality results.[2][8]
Consumer behavior & competition
Consumer-facing platforms increasingly combine blood testing with digital health services: Function offers more than 160 laboratory tests for $365 annually, while WHOOP promotes targeted panels covering 77 to 90 biomarkers and uses Quest Diagnostics' network of more than 2,000 locations. This indicates competition across subscriptions, biomarker breadth, interpretation and collection convenience, not only test-kit hardware.[7][9]
M&A
In April 2026, Function Health announced that it had acquired Getlabs, adding at-home and in-office blood-draw services to its consumer health platform. The transaction gives Function access to Getlabs' nationwide network of providers, health systems and partners, although financial terms were not disclosed.[7]
Regulation
In a U.S. FDA 510(k) document, Athelas Home is indicated for self-testing white blood cell and neutrophil percentages from capillary fingerstick blood in adults aged 21 and older at risk of neutropenia. FDA states that home-use tests are regulated medical devices and maintains a searchable database of approved or cleared home and laboratory tests.[10][8]
Latest news
The most significant recent industry development identified was Function Health's April 8, 2026 acquisition of Getlabs. Function said members would be able to choose between testing at more than 2,000 Quest Diagnostics locations and at-home or in-office blood draws through Getlabs.[7]

02 Ranking

Top 9 Companies in the At Home Blood Testing Industry

The leading companies in the at home blood testing industry, ranked on market impact, performance, momentum, innovation and brand popularity.

Updated November 18, 2026 · Next review December 18, 2026

Verdict

Labcorp stands out for consumer-ordered and at-home diagnostic testing because Labcorp OnDemand lets consumers request lab tests including at-home collection kits, while Quest Diagnostics focuses on self-collected diagnostic testing since Quest Health offers more than 150 tests through its consumer-initiated testing platform.

Ranked by Overall score · How we score ↓

Editor's top 3 picks

Where to start, by need.

  1. #1 Overall · Leader in consumer testing platforms

    Labcorp

    US

    Ranked #1 · 9.3 · Consumer testing platforms

    Why we picked it: It serves the consumer-ordered and at-home diagnostic testing segment through at-home collection kit requests.

  2. Leader in at-home collection devices

    Tasso

    US

    Ranked #3 · 9.0 · At-home collection devices

    Why we picked it: It focuses on self-collection blood sampling devices built for out-of-clinic whole-blood collection.

  3. Leader in service-inclusive at-home testing

    Fuze Health

    US

    Ranked #4 · 8.5 · Service-inclusive at-home testing

    Why we picked it: It combines at-home testing and clinical services, including an at-home testing business in its portfolio.

Pick 1 is the #1 company overall. Picks 2 and 3 are the highest-ranked companies in the top 5 that add a new segment.

Full ranking

Sort by
Top 9 companies in the at home blood testing industry, 2026 – Gitnux ranking
#CompanyOverall ↓Company snapshot
1

Labcorp

Consumer testing platforms · US

9.3
2

Quest Diagnostics

Consumer testing platforms · US

9.0
3

Tasso

At-home collection devices · US

9.0
4

Fuze Health

Service-inclusive at-home testing · US

8.5
5

SiPhox Health

At-home collection devices · US

8.3
6

Medichecks

Mail-in laboratory sampling · GB

8.1
7

imaware

Mail-in laboratory sampling · US

8.0
8

myLAB Box

Mail-in laboratory sampling · US

7.8
9

Thriva

Subscription at-home monitoring · GB

7.4

How we score

  • Impact (30%): scale and weight in the market (revenue, market share, employees, market position).
  • Performance (20%): recent revenue growth and operating margin; an analyst assessment where a company does not publish them.
  • Momentum (20%): growth trajectory and future potential.
  • Innovation (15%): R&D intensity and how technologically advanced the company is.

Popularity (brand search demand, 15%) counts toward Overall but is not published as a column. Overall leaves out what is not known.

Scale Scores are shown on a 7–10 scale with one decimal; bars start at 7.0.

Cadence Recalculated when new figures are published; next review December 18, 2026.

Independence. Rankings are editorially independent. Scores, ranks, picks and the verdict follow the method above; no company can pay to change them.

Cite this ranking

APA

Samuel Norberg. (2026, November 19). Top 9 companies in the at home blood testing industry. In At Home Blood Testing Industry Statistics. Gitnux. https://gitnux.org/at-home-blood-testing-industry-statistics/#top-companies

report visual · Comparison

Home blood testing services market share by region

North America holds the largest share at 45.3%.

North America45.3%
Europe29.5%
Asia Pacific17.2%
Latin America4.9%
Middle East and Africa3.1%
source-verifiedpmarketresearch.com

04 Statistics

Market Intelligence

Market size data anchors the category: $193.4M in 2025 and $210.1M in 2026, with a path to $382.0M by 2033 at an 8.9% CAGR.

Market size and service revenue in the at home blood testing industry

  • USD 93.5 million was the global 2024 market for at-home blood collection devices, defined as lancets and DBS kits used for liquid or dried blood collection across diagnostics, screening and clinical trials.[1]
  • USD 63.2 million was U.S. 2025 revenue for at-home blood collection kits and devices, defined by product as DBS kits, microsampling devices, fingerstick kits, lancets and capillary tubes.[2]
  • USD 193.4 million was the global 2025 market for at-home blood collection kits and devices, defined as self-collection and professional-assisted home devices, including DBS kits, microsampling devices, fingerstick kits, lancets and capillary tubes.[2]

Growth forecasts for the at home blood testing industry

  • The global at-home blood collection kits and devices market is projected to reach USD 382.0 million by 2033 from USD 210.1 million in 2026, a CAGR of 8.9% for 2026–2033; the category covers self-collection and professional-assisted home devices.[2]
  • The global at-home blood collection devices market is projected to reach USD 135.0 million by 2029 from USD 93.5 million in 2024, implying a 7.6% CAGR for 2024–2029; the category covers lancets, DBS kits and related collection devices.[1]
  • The U.S. at-home blood collection kits and devices market is projected to reach USD 115.2 million by 2033, growing at a 7.8% CAGR from 2026 to 2033; the category covers DBS kits, microsampling devices, fingerstick kits, lancets and capillary tubes.[2]

05 Statistics

Operating Benchmarks

Collection performance shows variability by device and study design, including Tasso-SST’s 4.4% collection-failure rate across investigational and implementation phases in Canada.

Operating metrics used in the at home blood testing industry

  • The Tasso-SST home blood self-collection device had a 4.4% collection-failure rate across the study’s adult and pediatric investigational and implementation phases in Canada.[3]
  • 70.5% of 32,671 registered households completed a California at-home dried-blood-spot study by returning an adequate blood sample and completing the survey during the study period.[4]
  • The median blood volume collected with a Tasso-SST home self-collection device was 425 microlitres across adult and pediatric study participants in Canada, with the study assessing remote clinical-trial sampling.[3]

06 Statistics

Risk & Compliance

Compliance timing is specific: HIPAA breach notice phone numbers must remain active for 90 days, and covered-entity and business-associate notification deadlines are 60 calendar days and 60 calendar days after discovery, respectively.

Client data and confidentiality in the at home blood testing industry

  • 90 days is the minimum period a toll-free telephone number must remain active in individual HIPAA breach notices when at-home blood-testing client information is involved.[5]
  • 500 affected individuals is the threshold requiring covered entities to notify the HHS Secretary without unreasonable delay and no later than 60 calendar days after discovering a breach.[5]
  • 60 calendar days is the maximum period for a HIPAA business associate handling at-home blood-testing information to notify the covered entity after discovering a breach of unsecured protected health information.[5]

Key questions about the at home blood testing industry

What is the market size for at-home blood collection kits and devices in 2026?
The global at-home blood collection kits and devices market is estimated at $210.1 million in 2026.
How fast is the market expected to grow after 2026?
It is forecast to reach $382.0 million by 2033, representing an 8.9% compound annual growth rate from 2026 to 2033.
Which companies lead the at home blood testing industry?
Labcorp stands out for consumer-ordered and at-home diagnostic testing because Labcorp OnDemand lets consumers request lab tests including at-home collection kits, while Quest Diagnostics focuses on self-collected diagnostic testing since Quest Health offers more than 150 tests through its consumer-initiated testing platform.
What technology shift is driving demand in this market?
Self-collection continues gaining share, with self-collection devices holding a 60.2% share of the 2025 device market.
How is the market structured between devices and kit categories?
Dried blood spot kits represented the largest product segment at 39.9% in 2025, while self-collection devices led by device type with a 60.2% share.
What is the typical pricing structure difference between collection and testing in the U.S.?
Quest Diagnostics charges a $79 fee for in-home sample collection and shipment of samples to a Quest laboratory, while laboratory testing is billed separately.
Reference

Cite This Report

This report is designed to be cited. We maintain stable URLs and versioned verification dates. Copy the format appropriate for your publication below.

APA
Samuel Norberg. (2026, November 19). At Home Blood Testing Industry Statistics. Gitnux. https://gitnux.org/at-home-blood-testing-industry-statistics
MLA
Samuel Norberg. "At Home Blood Testing Industry Statistics." Gitnux, 19 Nov 2026, https://gitnux.org/at-home-blood-testing-industry-statistics.
Chicago
Samuel Norberg. 2026. "At Home Blood Testing Industry Statistics." Gitnux. https://gitnux.org/at-home-blood-testing-industry-statistics.